Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ANTA PHAR       

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Anthera Pharmaceuticals Inc : Faruqi & Faruqi, LLP is Investigating Anthera Pharmaceuticals Incorporated on Behalf of its Shareholders - ANTH

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/13/2013 | 02:05pm CEST

NEW YORK, Feb. 13, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights, consumer rights and the enforcement of federal antitrust laws, is investigating potential claims against the board of directors of Anthera Pharmaceuticals Incorporated ("Anthera" or the "Company") (Nasdaq: ANTH) concerning possible breaches of fiduciary duty and other violations of law related to the Company's compensation packages for its executive officers. The investigation focuses on the approval and awarding of certain stock options to executives that may have violated the Company's compensation plans.

(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO)

Request more information now by clicking here: www.faruqilaw.com/ANTH

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action and derivative litigation. The firm is focused on providing exemplary legal services in the areas of securities, shareholder, antitrust and consumer litigation, through all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients.

If you hold ANTH shares and you would like to discuss your legal rights, visit www.faruqilaw.com/ANTH. You can also contact us by calling Michael J. Hynes free at 877-247-4292 or at 215-277-5770 or by sending an e-mail to [email protected]

Contact:

Faruqi & Faruqi, LLP
Michael J. Hynes, Esq.
101 Greenwood Avenue Suite 600
Jenkintown, PA 19046
Telephone: (877) 247-4292 or (215) 277-5770
E-mail: [email protected]

(Nasdaq: ANTH)

Attorney Advertising. (C) 2013 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ANTA PHAR
05/25 ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Other Events
05/25 ANTHERA PHARMACEUTICALS INC : Other Events (form 8-K)
05/18 ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Notice of Delisting or..
05/18 ANTHERA PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Contin..
05/15 Anthera Announces First Patient Screened in RESULT Pivotal Phase 3 Clinical S..
05/10 ANTHERA PHARMACEUTICALS : reports 1Q loss
05/10 ANTHERA PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fin..
05/10 Anthera Pharmaceuticals Provides Business Update and Reports 2017 First Quar..
05/01 ANTHERA PHARMACEUTICALS INC : REVERSE SPLIT: 1 for 8
2013 ANTHERA PHARMACEUTICALS INC : Anthera Pharmaceuticals Announces 1-for-8 Reverse ..
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Bio Therapeutic Drugs